Clinical trial
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
NCT00175955 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00175955 |
|---|---|
| Title | Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia |
| Official title | An 8-week Exploratory, Double-blind, Placebo Controlled, Randomized Trial: Evaluation of the Efficacy and Safety of Levetiracetam up to 3000 mg/Day (250-500 mg Oral Tablets in b.i.d. Administration) on Neuroleptic-induced Tardive Dyskinesia in Subjects With Stable Axis I Psychiatric Disorder, Aged… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dyskinesia, Medication-induced |
| Intervention type | Drug |
| Interventions | Levetiracetam |
| Enrollment | 70 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 6, 2013 |
| Countries | Belgium, Bulgaria |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: